Company intelligence / Profile preview

Lynx Dx

Ann Arbor, Michigan, United Stateslynxdx.com ↗

Ownership: Private
Development stage: Commercial

Overview

Lynx Dx has developed and commercialized non-invasive urine-based molecular diagnostic tests—MyProstateScore™ and its next-generation version, MyProstateScore 2.0—for early detection of clinically significant prostate cancer. These tests combine analysis of multiple gene transcripts with PSA levels to provide individualized risk assessments, reducing unnecessary biopsies. MPS2 analyzes an expanded panel of 18 unique gene transcripts for improved accuracy[1][4]. Peer-reviewed studies confirm analytical validity; MPS/MPS2 is now covered by Medicare[6].

Therapeutic areas: Oncology
Modalities: Diagnostic test (molecular diagnostic)Biomarker-based assay
Industry: Molecular Diagnostics

Drug pipeline

1 asset

MyProstateScore 2.0

Commercial

Indications: Prostate cancer

Beyond the preview

Go deeper on Lynx Dx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lynx Dx.

Explore the full profile